Display options
Cite
Miles B, Mackey JD. Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients. Cureus. 2021;13(7):e16372doi: 10.7759/cureus.16372.
Miles, B., & Mackey, J. D. (2021). Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients. Cureus, 13(7), e16372. https://doi.org/10.7759/cureus.16372
Miles, Brittany, and Mackey, James D. "Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients." Cureus vol. 13,7 (2021): e16372. doi: https://doi.org/10.7759/cureus.16372
Miles B, Mackey JD. Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients. Cureus. 2021 Jul 13;13(7):e16372. doi: 10.7759/cureus.16372. eCollection 2021 Jul. PMID: 34422458; PMCID: PMC8366185.
Copy Download .nbib Format: NLM
Share it on

Cureus. 2021 Jul 13;13(7):e16372. doi: 10.7759/cureus.16372. eCollection 2021 Jul.

Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients.

Cureus

Brittany Miles, James D Mackey

Affiliations

  1. Medical Education, University of Texas Medical Branch, Galveston, USA.
  2. Radiology, University of Texas Medical Branch, Galveston, USA.
  3. Medical Oncology, Baylor University Medical Center, Dallas, USA.

PMID: 34422458 PMCID: PMC8366185 DOI: 10.7759/cureus.16372

Abstract

Background The landscape for patients with multiple myeloma has improved dramatically over the last 15 years. Immunomodulatory imide drugs (IMiDs) have shown great efficacy in both the setting of initial therapy and as maintenance after autologous stem cell transplant (ASCT). Concern has arisen, however, regarding the risk of second primary malignancies (SPMs) that appear to be associated with the use of IMiD agents. SPMs are a known sequela of multiple myeloma treatment, particularly as a consequence of maintenance lenalidomide status-post stem cell transplant (SCT). The benefit of SCT has become less clear with the utilization of newer, more effective initial therapies. Objectives To determine the effect of SCT on SPM risk and overall survival in multiple myeloma patients at 5 and 10 years after treatment initiation. Methods We used TriNetX, a global federated health research network providing access to electronic medical records (diagnoses, procedures, medications, laboratory values, genomic information) from approximately 58 million patients in 49 large healthcare organizations. We created two patient cohorts who had all received treatment with thalidomide, lenalidomide, or pomalidomide. One cohort had received SCT while the other had not. Both cohorts were then analyzed for the development of all non-myeloma malignancies which occurred at least one year after initiation of treatment. Results At 5 years, SPMs were 5.8% more likely in patients who received stem cell transplant (22.4% vs 16.6%, RR 0.741, p value <0.0001) but 5-year survival favored transplanted patients by 2.38% (64.85% vs 62.474%, p value 0.0044). 10-year survival favored patients who did not receive transplant by 1.44% (42.279% vs 40.838%, p value 0.0279). The Kaplan-Meier curves cross at year 6. Conclusions It has previously been shown that the use of alkylating agents in myeloma patients significantly increases the risk of SPM, but that difference had curiously not been shown to have a negative impact on survival. Our analysis shows that this negative survival impact does exist but requires six or more years of follow up to become evident. Recent analyses from studies using older regimens show no overall survival benefit from the use of stem cell transplant. As non-transplant regimens become more effective at producing minimal residual disease (MRD) negativity, it seems that transplantation for myeloma patients will soon be regarded as unnecessary or even detrimental.

Copyright © 2021, Miles et al.

Keywords: immunomodulatory imide drugs; multiple myeloma; second primary malignancies; stem cell transplant; trinetx

Conflict of interest statement

The authors have declared that no competing interests exist.

References

  1. Blood Cancer J. 2013 Jun 28;3:e121 - PubMed
  2. N Engl J Med. 2012 May 10;366(19):1782-91 - PubMed
  3. Lancet Oncol. 2014 Mar;15(3):253-4 - PubMed
  4. Best Pract Res Clin Haematol. 2020 Mar;33(1):101144 - PubMed
  5. Blood. 2011 Oct 13;118(15):4086-92 - PubMed
  6. J Clin Oncol. 2017 Oct 10;35(29):3279-3289 - PubMed
  7. Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):98-101 - PubMed
  8. N Engl J Med. 2012 May 10;366(19):1770-81 - PubMed
  9. Leuk Lymphoma. 2016 Sep;57(9):2228-31 - PubMed
  10. Clin Lymphoma Myeloma Leuk. 2012 Apr;12(2):113-7 - PubMed
  11. Int J Hematol. 2019 Jan;109(1):98-106 - PubMed
  12. Blood. 2012 Mar 22;119(12):2764-7 - PubMed
  13. Blood. 2012 Mar 22;119(12):2731-7 - PubMed
  14. N Engl J Med. 2017 Apr 6;376(14):1311-1320 - PubMed
  15. Leuk Lymphoma. 2015;56(11):3012-21 - PubMed
  16. Biol Blood Marrow Transplant. 2013 Feb;19(2):260-5 - PubMed
  17. Oncology. 1977;34(1):20-4 - PubMed
  18. Leuk Lymphoma. 2017 Mar;58(3):560-568 - PubMed

Publication Types